ENDURONYL
LOE ApproachingNDAORALTABLET
Approved
Aug 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ENDURONYL is an oral tablet approved in 1961 by Abbott with unknown mechanism of action and indication profile. The drug's exact therapeutic target and clinical use cannot be determined from available data.
LOE Approaching
Product approaching loss of exclusivity with minimal commercial data; team likely focused on transition planning and cost containment rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and approaching LOE status indicate this is a mature, declining product with minimal hiring momentum. Career opportunities are primarily in legacy brand management and transition planning rather than growth-oriented roles.
Brand ManagerMarket Access Specialist
Worked on ENDURONYL at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.